(Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.https://mf.feeds.reuters.com/c/871/f/...b6ed436/mf.gif
https://da.feedsportal.com/r/16487664...b6ed436/a2.imghttps://pi.feedsportal.com/r/16487664...6ed436/a2t.img
More...